BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21804629)

  • 21. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCR/ABL rearrangement in Philadelphia chromosome negative CML patients.
    Rerkamnuaychoke B; Jomsawat U; Maneesri N; Apilugsanachit A; Pattanasak N
    J Med Assoc Thai; 2000 Mar; 83 Suppl 1():S70-5. PubMed ID: 10865410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
    Warmuth M; Danhauser-Riedl S; Hallek M
    Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
    Horváth A; Baghiu MD; Pap Z; Bănescu C; Mărginean CO; Pávai Z
    Rom J Morphol Embryol; 2011; 52(3):907-13. PubMed ID: 21892537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
    ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
    Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
    Vaidya S; Vundinti BR; Shanmukhaiah C; Chakrabarti P; Ghosh K
    PLoS One; 2015; 10(1):e0114828. PubMed ID: 25629972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications].
    Tian J; Cheng H; Xu KL; Pan XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1056-60. PubMed ID: 19698259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
    Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Shi HL; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):409-12. PubMed ID: 15355693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
    Sattler M; Salgia R
    Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.
    Harada Y; Nishiwaki S; Sugimoto T; Onodera K; Goto T; Sato T; Kamoshita S; Kawashima N; Seto A; Okuno S; Yamamoto S; Iwasaki T; Ozawa Y; Miyamura K; Akatsuka Y; Sugiura I
    Medicine (Baltimore); 2017 Dec; 96(50):e9160. PubMed ID: 29390324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia.
    Hessner MJ; Roth MS; Drobyski WR; Baxter-Lowe LA
    Genet Anal Tech Appl; 1994; 11(4):90-4. PubMed ID: 7857690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
    Yanagi M; Shinjo K; Takeshita A; Tobita T; Yano K; Kobayashi M; Terasaki H; Naoe T; Ohnishi K; Ohno R
    Leukemia; 1999 Apr; 13(4):542-52. PubMed ID: 10214860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
    Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
    Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.